title: Intravenous iron supplementation after kidney transplantation.
abstract: BACKGROUND
  We sought to evaluate the effect of intravenous (IV) iron supplementation on hemoglobin (Hb) levels and detect predictors for response.
  
  
  METHODS
  This is a retrospective cohort study of 81 patients who were treated with IV iron post-transplant. We evaluated predictors of response to treatment defined as an increase in Hb value of more than 1 g/dL by linear regression analysis.
  
  
  RESULTS
  Three months after treatment, the mean Hb level increased significantly from 9.8 ± 1.4 g/dL to 11.1 ± 1.6 g/dL (p < 0.001). A lower baseline Hb value (OR: 0.51, 95% CI: 0.33-0.78 per 1 g/dL increase) was the only predictor of response at three months. The Hb value in the evaluable 60 patients at one yr increased from 9.9 ± 1.4 g/dL to 11.7 ± 1.7 g/dL (p < 0.001). Lower baseline Hb value (OR: 0.34, 95% CI: 0.18-0.65 per 1 g/dL increase) and a shorter time from transplantation (OR: 0.8, 95% CI: 0.68-0.94 per one yr increase) were predictors of response. Adverse events were reported in five patients (0.7% of doses). The rate of estimated glomerular filtration rate decline was reduced following the IV iron treatment -0.34 ± 1.05 mL/min/month after treatment compared with -0.81 ± 1.11 mL/min/month before treatment (p = 0.013).
  
  
  CONCLUSIONS
  IV iron treatment was safe and associated with Hb increase in a cohort of patients after kidney transplantation.
authors.affiliation: Department of Neprology and Hypertension, Rabin Medical Center, Petah Tikva, Israel. benayarz@gmail.com
authors.forename: Benaya
authors.initials: B
authors.lastname: Rozen-Zvi
authors.forename: Anat
authors.initials: A
authors.lastname: Gafter-Gvili
authors.forename: Boris
authors.initials: B
authors.lastname: Zingerman
authors.forename: Rachel S
authors.initials: RS
authors.lastname: Levy-Drummer
authors.forename: Liora
authors.initials: L
authors.lastname: Levy
authors.forename: Eitan
authors.initials: E
authors.lastname: Mor
authors.forename: Uzi
authors.initials: U
authors.lastname: Gafter
authors.forename: Ruth
authors.initials: R
authors.lastname: Rahamimov
mesh_terms: D061605:Administration, Intravenous; D000740:Anemia / Q000209:etiology / Q000517:prevention & control*; D019587:Dietary Supplements; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D006454:Hemoglobins; D007501:Iron